FOLH1 and prostate carcinoma: For example, in a phase I/II dose escalation trial, patients with biochemically recurrent prostate cancer were immunised i.m. with pDOM-PSMA, a DNA fusion vaccine encoding a PSMA epitope, PSMA27, and DOM, a domain of fragment C a tetanus toxin, without (Arm I) or with (Arm II) EP [48].